FDA Approves Kura's Ziftomenib (Komzifti) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible NPM1 Mutation

The FDA has approved Komzifti for adults facing difficult-to-treat AML linked to a specific NPM1 gene change.